Steatohepatitis Clinical Trials

87 recruitingLast updated: June 18, 2026

There are 87 actively recruiting steatohepatitis clinical trials across 53 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4. Top locations include Richmond, Virginia, United States, Houston, Texas, United States, San Antonio, Texas, United States. Updated daily from ClinicalTrials.gov.


Steatohepatitis Trials at a Glance

87 actively recruiting trials for steatohepatitis are listed on ClinicalTrialsFinder across 6 cities in 53 countries. The largest study group is Phase 2 with 25 trials, with the heaviest enrollment activity in Richmond, Houston, and San Antonio. Lead sponsors running steatohepatitis studies include 89bio, Inc., Boehringer Ingelheim, and Corcept Therapeutics.

Browse steatohepatitis trials by phase

Treatments under study

About Steatohepatitis Clinical Trials

Looking for clinical trials for Steatohepatitis? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Steatohepatitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Steatohepatitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 87 trials

Recruiting
Phase 2

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Madrigal Pharmaceuticals, Inc.120 enrolled17 locationsNCT07335601
Recruiting
Phase 3

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Metabolic Dysfunction-Associated Steatohepatitis
Boehringer Ingelheim1,590 enrolled447 locationsNCT06632457
Recruiting
Phase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled526 locationsNCT06632444
Recruiting
Phase 2

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

Metabolic Dysfunction-Associated Steatohepatitis
Eccogene160 enrolled58 locationsNCT07288138
Recruiting
Phase 3

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled322 locationsNCT06528314
Recruiting

Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

Type 2 Diabetes Mellitus (T2DM)MASH - Metabolic Dysfunction-Associated SteatohepatitisMetabolic Dysfunction-associated Fatty Liver Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School10,000 enrolled22 locationsNCT07632677
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled303 locationsNCT06419374
Recruiting
Phase 3

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled349 locationsNCT06318169
Recruiting

Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease

FibrosisNonalcoholic SteatohepatitisNonalcoholic Fatty Liver Disease+1 more
Peking Union Medical College Hospital2,000 enrolled1 locationNCT05330923
Recruiting
Phase 2

A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

MASH - Metabolic Dysfunction-Associated SteatohepatitisT2DM (Type 2 Diabetes Mellitus)
Shanghai Jiao Tong University School of Medicine300 enrolled17 locationsNCT07303803
Recruiting
Not Applicable

Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis
University of Minnesota48 enrolled4 locationsNCT03587831
Recruiting

Identification of Liver Fibrosis Biomarkers

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisNon-alcoholic Fatty Liver
Roche Diagnostics GmbH575 enrolled2 locationsNCT06819917
Recruiting
Phase 2

Digoxin In NASH (CODIN)

MASLDMASH - Metabolic Dysfunction-Associated SteatohepatitisFatty Liver Disease+5 more
Yale University144 enrolled2 locationsNCT06588699
Recruiting
Phase 1

Evaluating the Pharmacokinetics and Safety of Miricorilant

Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Phase 2

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Metabolic dysfunction-associated steatohepatitis (MASH)
Regeneron Pharmaceuticals120 enrolled71 locationsNCT05519475
Recruiting
Phase 1Phase 2

Study of TGM-312-SC01 in Healthy Participants and Adults With MASH

Healthy ParticipantsMASH - Metabolic Dysfunction-Associated Steatohepatitis
Tangram Therapeutics Plc99 enrolled1 locationNCT07427680
Recruiting
Not Applicable

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

NASH - Nonalcoholic Steatohepatitis
Perspectum225 enrolled7 locationsNCT04054310
Recruiting
Phase 2

A Study of CS060380 Tablets in Patients With MASH and Obesity

Metabolic dysfunction-associated steatohepatitis (MASH)Obesity
Cascade Pharmaceuticals, Inc120 enrolled12 locationsNCT07466017
Recruiting
Phase 2

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Rivus Pharmaceuticals, Inc.180 enrolled31 locationsNCT07491458
Recruiting
Phase 2

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)84 enrolled1 locationNCT03884075